Holen Sie sich die Stockscreener-App
3.4868
1.54%
-0.0532
Schlusskurs vom Vortag:
$3.54
Offen:
$3.58
24-Stunden-Volumen:
316.14K
Relative Volume:
0.61
Marktkapitalisierung:
$1.09B
Einnahmen:
$548.10M
Nettoeinkommen (Verlust:
$69.50M
KGV:
15.14
EPS:
0.2303
Netto-Cashflow:
$-137.90M
1W Leistung:
-13.08%
1M Leistung:
-24.88%
6M Leistung:
-56.59%
1J Leistung:
-68.82%
1-Tages-Spanne:
$3.475
$3.63
1-Wochen-Bereich:
$3.475
$4.08
52-Wochen-Spanne:
$3.475
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.49 | 1.10B | 548.10M | 69.50M | -137.90M | 0.2303 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.02 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.05 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.77 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
541.12 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-11-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech (NASDAQ:ALVO) Hits New 52-Week LowTime to Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.65 USD - Investing.com Nigeria
Alvotech, Advanz Pharma get EU nod for Eylea biosimilar - MSN
Alvotech (ALVO) Projected to Post Earnings on Wednesday - MarketBeat
Will Alvotech stock attract ESG investorsCPI Data & AI Enhanced Trading Signals - Naître et grandir
Alvotech Stock Plummets to New 52-Week Low of $3.65 - Markets Mojo
ALVO Earnings History & Surprises | EPS & Revenue Results | ALVOTECH SA (NASDAQ:ALVO) - ChartMill
Alvotech to Release Fourth Quarter and Full Year 2025 Financial Results - geneonline.com
Alvotech to Announce Q4 and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Alvotech (ALVO) Stock Analysis: Exploring A Potential 375% Upside In The Biosimilar Market - DirectorsTalk Interviews
Alvotech : Managers' transactionsALVOTECH - marketscreener.com
Alvotech stock hits 52-week low at 3.89 USD By Investing.com - Investing.com South Africa
Alvotech’s Biosimilar Bet: Why Wall Street Is Suddenly Watching - AD HOC NEWS
Alvotech (ALVOW) Competitors - Meyka
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.89 USD - Investing.com
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group - TipRanks
Alvotech (NASDAQ: ALVO) discloses 2.7M-share intra-group transfer at $4.74 - Stock Titan
Transactions of Managers and Closely Associated Persons - GlobeNewswire
Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe - simplywall.st
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech - GlobeNewswire
Alvotech begins European rollout of first-ever Simponi biosimilar Gobivaz - MSN
Alvotech (NASDAQ:ALVO) Cut to Strong Sell at Zacks Research - Defense World
Alvotech (NASDAQ:ALVO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Alvotech stock hits 52-week low at $4.31 amid challenging year - Investing.com Australia
Alvotech (NASDAQ:ALVO) Reaches New 1-Year LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Trading Down 5.7%Here's Why - MarketBeat
Alvotech (ALVO): A 378% Upside Potential In The Biosimilar Market - DirectorsTalk Interviews
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? - simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump - Yahoo Finance
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook - Yahoo Finance
How Alvotech Equity Warrant stock performs during Fed tightening cyclesEarnings Overview Summary & Free Safe Capital Growth Stock Tips - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateQuarterly Trade Summary & Accurate Entry and Exit Point Alerts - mfd.ru
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 - Finviz
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
12 Best Penny Stocks That Will Skyrocket - Insider Monkey
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - ChartMill
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):